Enhanced degradation of tryptophan in patients on hemodialysis

Clinical Nephrology

Volumn 74, Issue 6, 2010, Pages 465-470

  Koenig, P ^a   Nagl, C ^b   Neurauter, G ^b   Schennach, H ^c   Brandacher, G ^b   Fuchs, D ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Chronic hemodialysis; Indoleamine 2,3 dioxygenase; INTERMED score; Neopterin; Tryptophan

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD DONOR; BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PSYCHOLOGIC TEST; SLEEP DISORDER;

EID: 78649845438     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74465     Document Type: Article

References (29)

1. Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol. 2001; 33: 399-404.
2. Taylor MW, Feng GS. Relationship between interferon- gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. Faseb J. 1991; 5: 2516-2522.
3. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol. 1999; 116: 435-440.
4. Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/ psychiatric symptoms. J Aquir Immune Defic Syndr. 1990; 3: 873-876.
5. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metabol. 2002; 3: 175-187.
6. Schroecksnadel K, Wirleitner B,Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006; 364: 82-90.
7. Brandacher G, Cakar F, Winkler C, Schneeberger S, Obrist P, Bösmüller C, Werner-Felmayer G, Werner ER, Bonatti H, Margreiter R, Fuchs D. Non invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 2007; 71: 60-67.
8. Fuchs D, Hausen A, ReibneggerG,Werner ER, von Dittrich P, Wachter H. Neopterin levels in longterm hemodialysis. Clin Nephrol. 1988; 30: 220-224.
9. Godai K, Uemasu J, Kawasaki H. Clinical significance of serum and urinary neopterins in patients with chronic renal disease. Clin Nephrol. 1991; 36: 141-146.
10. Witko-Sarsat V, FriedlanderM, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49: 1304-1313.
11. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J,WachterH. Immune response-associated production of neopterin - Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984; 160: 310-316.
12. Wirleitner B, Reider D, Ebner S, BöckG,Widner B, Jaeger M, Schennach H, Romani N, Fuchs D. Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol. 2002; 72: 1148-1153.
13. Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant. 2002; 17 (Suppl): 16-24.
14. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007; 20: 440-451.
15. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002; 297: 1867-1870.
16. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D. Neopterin production tryptophan degradation and mental depression: what is the link? Brain Behav Immun. 2002; 16: 590-595.
17. Huang A, FuchsD,Widner B,Glover C, Henderson DC, Allen-Mersh TG. Tryptophan decrease in advanced colorectal cancer correlates with immune activation and impaired quality of life. Brit J Cancer. 2002; 86: 1691-1696.
18. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9: 46-56.
19. O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009; 14: 511-522.
20. Viljoen M, Bipath P, Govender C, Potgieter CD. Quality of life and tryptophan levels in chronic renal failure patients on hemodialysis. Clin Nephrol. 2008; 70: 561-562.
21. Hoogervorst EL, de Jonge P, Jelles B, Huyse FJ, Heeres I, van der Ploeg HM, Uitdehaag BM, Polman CH. TheINTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment J. Neurol Neurosurg Psychiatry. 2003; 74: 20-24.
22. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997; 43: 2424-2426.
23. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem. 2002; 48: 579-581.
24. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U.S.A. 1984; 81: 908-12.
25. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci U.S.A. 1988; 85: 1242-1246.
26. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ. IFN-gamma production by alloantigen-reactive regulatory Tcells is important for their regulatory function in vivo. J Exp Med. 2005; 201: 1925-1935.
27. Schroecksnadel K, Fiegl M, Prassl K, Winkler C, Denz HA, Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol. 2007; 133: 477-485.
28. Neurauter G, Schröcksnadel K, Scholl-Bürgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, Fuchs D. Chronic immune stimulation correlates with reduced phenylalanine turn-over. Curr Drug Metabol. 2008; 9: 622-627.
29. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994; 40: 288-295.